← Leaderboards
David R Sherman
University Of Washington
$26,094,329
Attributed
$36,378,388
Total exposure
22
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.9M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$76,608,068 · 25
By mechanism
U19$60,317,709 · 10
R01$8,767,352 · 4
P30$4,412,613 · 2
R21$1,648,840 · 4
R56$1,429,145 · 2
M01$16,409 · 1
Top collaborators
- Alan A Aderem26 shared
- David Alland5 shared
- Nitin S Baliga5 shared
- Rhea N Coler5 shared
- Chetan Seshadri5 shared
- Daniel E Zak5 shared
- Timothy R Sterling1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Evgeni Veniaminovic Sokurenko$27,635,025
- Beth A Traxler$1,776,811
- Alan A Aderem$59,360,862
- Lindley Barbee$1,414,990
- David W Russell$27,160,623
Others in their field
Top investigators on “Mycobacterium Tuberculosis”
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$267,251,837
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Kevin Urdahl · Seattle Children'S Hospital$86,597,961
- David Alland · Rutgers Biomedical And Health Sciences$70,943,567
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- William Robert Jacobs · Albert Einstein College Of Medicine$43,123,310
Research focus
Mycobacterium TuberculosisTuberculosisSystems BiologyGenesResponseDisease ProgressionNetwork ModelsProgramsPathogenTranscriptomicsIn VivoPhenotypeAffectBacteriaInfectionCessation Of LifeCellsGeneticPharmaceutical PreparationsPredispositionRegulator GenesProteinsDesignCommunities
Grant awards (84)
Seattle Tuberculosis Research Advancement Center$1,037,189
P30 · FY2025 · AI
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes$591,215
U19 · FY2025 · AI · contact PI
Development of novel agents to eliminate TB persisters$301,826
R21 · FY2025 · AI · contact PI
Core-004$176,571
P30 · FY2025 · AI
Seattle Tuberculosis Research Advancement Center$1,037,189
P30 · FY2024 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,613
R01 · FY2024 · AI · contact PI
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis$711,432
R01 · FY2024 · AI · contact PI
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes$579,083
U19 · FY2024 · AI · contact PI
Seattle Tuberculosis Research Advancement Center$1,043,145
P30 · FY2023 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,613
R01 · FY2023 · AI · contact PI
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis$721,199
R01 · FY2023 · AI · contact PI
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes$339,935
U19 · FY2023 · AI · contact PI
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes$133,208
U19 · FY2023 · AI · contact PI
Omics for TB: Response to Infection and Treatment$3,345,407
U19 · FY2022 · AI
Seattle Tuberculosis Research Advancement Center$1,118,519
P30 · FY2022 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,257
R01 · FY2022 · AI · contact PI
Project 2: Response to Treatment$746,072
U19 · FY2022 · AI · contact PI
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis$705,063
R01 · FY2022 · AI · contact PI
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes$143,673
U19 · FY2022 · AI · contact PI
Omics for TB: Response to Infection and Treatment$3,351,336
U19 · FY2021 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$812,107
R01 · FY2021 · AI · contact PI
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis$730,836
R01 · FY2021 · AI · contact PI
Project 2: Response to Treatment$584,650
U19 · FY2021 · AI · contact PI
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes$568,737
U19 · FY2021 · AI · contact PI
Omics for TB: Response to Infection and Treatment$3,351,478
U19 · FY2020 · AI
Genetic, Metabolic and Regulatory Control of MIC and Relapse in M. tuberculosis$851,389
R01 · FY2020 · AI · contact PI
A multifactorial pipeline to dissect combinatorial drug efficacy in Tuberculosis$733,199
R56 · FY2020 · AI · contact PI
Project 2: Response to Treatment$693,087
U19 · FY2020 · AI · contact PI
Omics for TB: Response to Infection and Treatment$3,359,502
U19 · FY2019 · AI
Project 2: Response to Treatment$452,538
U19 · FY2019 · AI · contact PI
Omics for TB: Response to Infection and Treatment$1,991,315
U19 · FY2018 · AI
Omics for TB: Response to Infection and Treatment$1,648,783
U19 · FY2018 · AI
Project 2: Response to Treatment$327,811
U19 · FY2018 · AI · contact PI
Project 2: Response to Treatment$218,245
U19 · FY2018 · AI · contact PI
Omics for TB Disease Progression (OTB)$3,780,715
U19 · FY2017 · AI
Host Determinants of TB Disease Progression$1,074,740
U19 · FY2017 · AI
Technology Core$889,513
U19 · FY2017 · AI
Bacterial Determinants of TB Progression$763,150
U19 · FY2017 · AI · contact PI
Modeling Core$582,660
U19 · FY2017 · AI
Data Management and Resource Dissemination Core$238,208
U19 · FY2017 · AI
Administrative Core$232,444
U19 · FY2017 · AI
Omics for TB Disease Progression (OTB)$3,989,779
U19 · FY2016 · AI
Administrative Core$904,831
U19 · FY2016 · AI
Host Determinants of TB Disease Progression$864,766
U19 · FY2016 · AI
Technology Core$794,278
U19 · FY2016 · AI
Fluoroquinolones and Efflux-Mediated Cross Resistance in HIV-related TB$695,946
R56 · FY2016 · AI
Bacterial Determinants of TB Progression$614,368
U19 · FY2016 · AI · contact PI
Modeling Core$473,646
U19 · FY2016 · AI
Data Management and Resource Dissemination Core$337,890
U19 · FY2016 · AI
Parallel Microscopic Determination of Fitness (PMDF) to Assess Growth and Viability of Mycobacterium tuberculosis$236,250
R21 · FY2016 · AI · contact PI
Omics for TB Disease Progression (OTB)$3,774,222
U19 · FY2015 · AI
Host Determinants of TB Disease Progression$978,239
U19 · FY2015 · AI
Technology Core$804,529
U19 · FY2015 · AI
Bacterial Determinants of TB Progression$777,985
U19 · FY2015 · AI · contact PI
Modeling Core$765,744
U19 · FY2015 · AI
Parallel Microscopic Determination of Fitness (PMDF) to Assess Growth and Viability of Mycobacterium tuberculosis$283,500
R21 · FY2015 · AI · contact PI
Administrative Core$270,977
U19 · FY2015 · AI
Data Management and Resource Dissemination Core$176,748
U19 · FY2015 · AI
Omics for TB Disease Progression (OTB)$4,075,407
U19 · FY2014 · AI
Host Determinants of TB Disease Progression$1,664,165
U19 · FY2014 · AI
Modeling Core$812,406
U19 · FY2014 · AI
Bacterial Determinants of TB Progression$669,878
U19 · FY2014 · AI · contact PI
Technology Core$480,181
U19 · FY2014 · AI
Administrative Core$244,843
U19 · FY2014 · AI
Data Management and Resource Dissemination Core$203,934
U19 · FY2014 · AI
Omics for TB Disease Progression (OTB)$3,325,694
U19 · FY2013 · AI
Technology Core$813,839
U19 · FY2013 · AI
Host Determinants of TB Disease Progression$787,288
U19 · FY2013 · AI
Modeling Core$774,605
U19 · FY2013 · AI
Bacterial Determinants of TB Progression$584,671
U19 · FY2013 · AI · contact PI
Administrative Core$186,497
U19 · FY2013 · AI
Data Management and Resource Dissemination Core$178,794
U19 · FY2013 · AI
2013 Tuberculosis Drug Development GRC$8,000
R13 · FY2013 · AI · contact PI
2011 Gordon Research Conference on Tuberculosis Drug Development$8,000
R13 · FY2011 · AI · contact PI
A Novel Clock to Monitor M. tuberculosis in vivo$241,000
R21 · FY2010 · HL · contact PI
A Novel Clock to Monitor M. tuberculosis in vivo$264,715
R21 · FY2009 · HL · contact PI
Hypoxia, Latency and Reactivation in M.tuberculosis$328,659
R01 · FY2006 · AI · contact PI
Hypoxia, Latency and Reactivation in M.tuberculosis$336,784
R01 · FY2005 · AI
Hypoxia, Latency and Reactivation in M.tuberculosis$351,008
R01 · FY2004 · AI
Hypoxia, Latency and Reactivation in M.tuberculosis$348,757
R01 · FY2003 · AI
EARLY PULMONARY HOST DEFENSE IN M. TUBERCULOSIS INFECTIO$266,000
R01 · FY2003 · HL
Hypoxia, Latency and Reactivation in M.tuberculosis$166,635
R01 · FY2002 · AI
Hypoxia, Latency and Reactivation in M tuberculosis$321,549
R21 · FY2001 · AI
ASPIRIN AND CAROTID ENDARTERECTOMY$16,409
M01 · FY2000 · RR